What happens when a $2 million gene therapy is not enough :

(This Aug. 12 story has been corrected to state that ICER's final analysis was that Zolgensma was cost effective at a price of $1.1 million to $1.9

Related Keywords

Kazakhstan , Columbus , Ohio , United States , Switzerland , Berwyn , Illinois , Chicago , Russia , Virginia , Lebanon , Americans , Deena Beasley , Roger Hajjar , Elizabeth Kutschke , Roche Evrysdi , Sitra Tauscher Wisniewski , Amanda Cook , Eric Cox , Sree Chaguturu , Sara Ledwith , Vasant Narasimhan , Maha Radhakrishnan , Steven Pearson , Stacie Dusetzina , Ben Kutschke , Caroline Humer , Russell Butterfield , Jerry Mendell , Aetna , Brigham Gene Cell Therapy Institute , Novartis , University Of Utah Health , Institute For Human Data Science , Institute For Clinical , Unitedhealth Group , Nashville Vanderbilt University School Of Medicine , Drug Administration , Reuters , Baby Ben Kutschke , Human Data , Novartis Gene , Mass General Brigham Gene , Cell Therapy , Vanderbilt University School , Economic Review , Chief Medical Officer Maha Radhakrishnan , Nationwide Children , Utah Health , Intermountain Primary Children ,